The Incannex (ASX:IHL) share price is surging 7% higher today. Here's why

The Incannex share price is soaring today as the company reported the outcome of its drug trials. We take a closer look.

| More on:
Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Incannex Healthcare Limited (ASX: IHL) share price has zoomed up today as the company announced positive results in its drug study results.

Shares in the bio tech small cap are currently trading 7.5% higher at 17 cents.

What Incannex does

Incannex is a clinical stage pharmaceutical development company in the cannabis industry. The company utilises medicinal cannabis products and psychedelic therapies for the treatment of obstructive sleep apnoea and traumatic brain injury among other things.

Incannex is pursuing FDA registration, subject to ongoing clinical success, for each product under development.

In addition, the company owns a license to import, export and distribute medicinal cannabis products and has launched a line of cannabinoid oil products. The products are sold under Incannex's product supply and distribution agreement with Cannvalate – a major shareholder of Incannex.

What's driving the Incannex share price?

Incannex shares are higher today as the company expands its IHL-675A drug to include more inflammatory lung conditions. This comes after the company received positive results from additional in vivo (animal) studies.

The drug IHL-675A combines CBD with hydroxychloroquine for anti-inflammatory purposes. Previous tests have shown it is excellent candidate for the prevention and treatment of sepsis associated acute respiratory distress syndrome (SAARDS).

Incannex has now expanded target indications with initial patent filings for IHL675A to include asthma, bronchitis, and other inflammatory lung conditions.

Furthermore, the company estimates that the global addressable drug market for its products will reach US$50.4 billion by 2022.

Management comments

Incannex Healthcare CEO Joel Latham welcomed the news, saying:

IHL-675A is consistently showing stronger anti-inflammatory properties than CBD. Continued research will reveal how important this will be to the cannabinoid sector in light of continued research globally on CBD and its application to inflammatory conditions.

The synergistic action of IHL-675A allows us to substantially expand the potential uses for IHL675A and presents new patient treatment opportunities.

About the Incannex share price

Shares in Incannex are rising today as the company reported favourable drug results.

The company's share price has soared in the last 6 months, up from 6 cents to 17 cents and banking an impressive 183.3% in the process.

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Woman with a concerned look on her face holding a credit card and smartphone.
Share Market News

I've got $10,000 cash. What's the harm if I don't invest it in the next 5 years?

Investors may be nervous to invest at the moment.

Read more »

Woman with a scared look has hands on her face.
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

A man looking at his laptop and thinking.
Share Market News

5 things to watch on the ASX 200 on Monday

Here's what to expect on the local market today.

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Share Gainers

These were the best-performing ASX All Ords shares in May

These shares caught the eye last month. What was getting investors excited?

Read more »

A man and a woman sitting in a technology-related work environment high five each other while the man wears headphones around his neck and the woman sits in front of a laptop.
Share Market News

Strong gains for Wisetech, TechnologyOne, and Catapult amid ASX 200 tech sector lead

ASX technology shares led the market with a 3.85% increase while the ASX 200 lifted 0.88% last week.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Warren Buffett
Share Market News

Could these Australian fund managers be the next Warren Buffett?

Buffett is widely regarded the world's most successful investor.

Read more »

Man with rocket wings which have flames coming out of them.
Broker Notes

These ASX 200 shares could rise 40%+

Big returns could be on offer from these shares according to analysts.

Read more »